| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.42 | 0.1 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.074 | 0.2 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |